As of 2025-08-25, the Intrinsic Value of GT Biopharma Inc (GTBP) is -14.19 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.11 USD, the upside of GT Biopharma Inc is -1,378.54%.
Based on its market price of 1.11 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 1,378.54%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.19 - -14.19 | -14.19 | -1,378.54% |
| P/E | (40.59) - (67.84) | (59.75) | -5482.6% |
| DDM - Stable | (20.08) - (63.45) | (41.76) | -3862.5% |
| DDM - Multi | (20.08) - (50.88) | (28.97) | -2710.1% |
| Market Cap (mil) | 4.56 |
| Beta | 0.43 |
| Outstanding shares (mil) | 4.11 |
| Enterprise Value (mil) | -0.66 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.96% |
| Cost of Debt | 5.00% |
| WACC | 7.32% |